Novozymes publishes data on Recombumin excipient
Novozymes Biopharma has published data demonstrating the ability of Recombumin, an excipient, to protect against aggregation, oxidation and non-specific adsorption.
These attributes make Recombumin an effective, multi-purpose excipient for improving shelf-life, according to Novozymes. The company added that manufacturers using Recombumin can reduce the total number of excipients required and simplify the formulation process.
Recombumin is derived from Novozymes’ proprietary yeast expression technology and is designed to offer the stabilising benefits if albumin in a good manufacturing practice (GMP) compliant regulatory package.
Compliance with the United States Pharmacopeia’s (USP) excipient monograph for recombinant human albumin further reduces the regulatory burden.
